JNJ : Analysis & Opinions

  • Showing 201-214 of 214 items
  • <<
  • 1
  • 2
  • 3
  1. No More Tears For Johnson & Johnson

    January 23, 2009
    Its wide range of products and international exposure give this stock a positive long-term outlook.
  2. Making Your Investments Pay: Equity Income ETFs

    December 4, 2008
    The flight to extreme quality has reduced treasury yields to non-inflation beating instruments. Income ETFs are now ripe ...
  3. A Matrixx For Killing The Common Cold

    November 3, 2008
    Matrixx Initiatives works to build a name for itself in the competitive over-the-counter cold medicine market.
  4. Aging Population Feeds Global Healthcare Demand

    October 30, 2008
    Investing in foreign-based healthcare providers is as important as investing in healthcare providers with a global reach.
  5. Is Stock Market Capitulation Over?

    October 15, 2008
    We examine the present market for clues to where and when we'll see a bottom.
  6. Back To The Basics: Safety And Diversification

    September 19, 2008
    With investors freaking out, it is time to examine a small portfolio of stocks to gain diversification and safety.
  7. CVS Posts Record Profits

    May 5, 2008
    Despite the slowing U.S economy, CVS is still going strong.
  8. Five Dividend Darlings For Your Portfolio

    April 24, 2008
    Does your portfolio lack a solid dividend yield? Here are five dividend-paying stocks to snap up while their yields are high.
  9. Johnson & Johnson Blows Away Q1 (JNJ)

    April 20, 2007
    J&amp;J beat its Q1 consensus number with ease, so where is the stock is headed from here?
  10. P/E Ratios Still Matter

    February 1, 2007
    High P/E stocks are almost always more glamorous than their low P/E counterparts, but are they more profitable?
  11. Bristol-Myers Hurt By Plavix, Saved By Demographics (BMY)

    November 16, 2006
    Despite BMY's recent struggles with its Plavix sales, favorable demographics make the stock a good investment to consider.
  12. Boston Scientific Shaken, But Not Stirred (BSX)

    November 8, 2006
    Boston Scientific looks poised for higher per share valuations in the future.
  13. Weakness At Target A Reason For Concern (TGT)

    July 18, 2006
    With an economic slowdown in the mix, Target may feel the pinch more than investors expect.
  14. Pfizer, Pass the Rolaids

    June 12, 2006
    $15 billion for its consumer products unit won’t cure Pfizer’s ailing stock.
  • Showing 201-214 of 214 items
  • <<
  • 1
  • 2
  • 3
Trading Center